DFTX: Oppenheimer Raises Target
Oppenheimer maintains Outperform rating on Definium Therapeutics and raises price target to $60
Oppenheimer Maintains Outperform on Definium Therapeutics, Raises Price Target to $60
Oppenheimer maintains Outperform rating on Definium Therapeutics and raises price target to $60
Oppenheimer Maintains Outperform on Definium Therapeutics, Raises Price Target to $60